Hemangiol, Post Marketing Surveillance Study

This study is retrospective, longitudinal, descriptive and observational. Children aged 0 to 1 years hospitalized for introduction of Hemangiol between January 2014 and November 2018 will be included. Patients refuse the use of medical data will be excluded. The main objective is to describe the population who received Hemangiol. The secondary objectives is to evaluate * the effectiveness of Hemangiol on proliferative infantile hemangiomas, -the tolerance of Hemangiol in children with proliferative infantile hemangiomas * the interest of systematic cardiological consultation in children with proliferative infantile hemangiomas receiving Hemangiol The following criteria will be collected Demographic description: age, sex, height, weight Personal history Description of the hemangioma: * organ concerned: skin, liver, parotid, mixed. * location: head, thorax, pelvis, limbs, diffuse ... * single or multiple * indication of treatment: aesthetic, functional, ulcerated, cardiac hyperacidity Rhythm of follow-up: duration of treatment and observance of treatment Prescribed dose: 1, 2, 3 or 4 mg / kg / day in 2 doses Evolution of the hemangioma: progression, regression, stagnation. Needed a second medical therapeutic line by specifying the treatment introduced. Necessity of surgical management by specifying the delay between surgery and the introduction of treatment Description of serious adverse events: hypotension, bradycardia, bronchospasm, hypoglycaemia. Description of other adverse events. Number of cardio-pediatric consultations, specifying: * incidence of diagnosed heart disease through systematic cardiac consultation * effect on ECG data of increasing dosage of Hemangiol: heart rate, PR duration, QRS duration, QT duration